Vortioxetine
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Vortioxetine: From Major Depressive Disorder to Neurotic Disorder
One-Sentence Summary
Vortioxetine is a multimodal serotonergic antidepressant whose approved use, according to the literature evidence collected here, is major depressive disorder (MDD). The TxGNN model predicts it may also be effective for Neurotic Disorder, but this direction is currently supported only by 1 real-world clinical study and 1 case-based review, with no dedicated randomized trial for this specific diagnostic label.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Major Depressive Disorder (MDD) — no EU marketing authorization record found in this Evidence Pack; indication inferred from literature describing vortioxetine as “currently approved for the treatment of major depressive disorder” |
| Predicted New Indication | Neurotic Disorder |
| TxGNN Prediction Score | 99.24% |
| Evidence Level | L3 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for vortioxetine is not available in the drug-level fields of this Evidence Pack (flagged as a High-severity data gap). However, supporting literature within the predicted-indication evidence describes vortioxetine as a multimodal serotonergic agent: it inhibits the serotonin transporter (SERT), acts as a 5-HT1A receptor agonist and 5-HT1B partial agonist, and antagonizes 5-HT3 and 5-HT7 receptors. This combined receptor profile increases serotonergic, noradrenergic, dopaminergic, and cholinergic neurotransmission in brain regions implicated in mood and anxiety regulation.
“Neurotic disorder” is a broad, largely obsolete ICD-9-era category encompassing anxiety–depressive spectrum conditions. Because vortioxetine’s serotonergic mechanism directly targets mood and anxiety circuitry, extrapolation to this category is mechanistically plausible. However, the repurposing rationale in the Evidence Pack explicitly notes that “neurotic disorder” substantially overlaps with the already-established MDD indication rather than representing a clearly distinct, novel therapeutic target — meaning this candidate sits closer to a labeling/nomenclature question than a true new indication.
The single supporting clinical study (NCT04446039) is a large real-world retrospective cohort comparing antidepressant utilization patterns across 370,212 patients, but it was not designed around this specific diagnostic label and provides only indirect supportive signal (relevance grade B). The one literature reference is a case-based review of neurotic depression treatment approaches, further reinforcing plausibility but not establishing direct efficacy evidence for this precise disease label.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04446039 | N/A | Completed | 370,212 | Real-world retrospective cohort study using nationwide claims data comparing utilization patterns and adverse-outcome risk across commonly used antidepressants; not specific to this diagnostic label but provides indirect supportive signal on overall antidepressant clinical benefit |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31006795 | 2019 | Review (case report) | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova | Discusses treatment approaches for neurotic depression, highlighting the benefit of combining antidepressant pharmacotherapy with cognitive behavioral therapy |
EU Market Information
No EU marketing authorization records are present in this Evidence Pack (total_licenses: 0). Market status is recorded as not marketed.
Safety Considerations
Please refer to the SmPC for safety information. No key warnings, contraindications, or drug–drug interaction data are currently available in this Evidence Pack (DDI query returned no results).
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to a single indirect real-world cohort study and one case-based review (Evidence Level L3), with no trial specifically designed around the “neurotic disorder” diagnostic label. Additionally, this candidate largely overlaps with vortioxetine’s already-recognized MDD indication rather than representing a clearly distinct repurposing opportunity, and a Blocking-severity safety data gap (missing label warnings/contraindications) prevents even an initial (S1) safety assessment.
To proceed, the following is needed:
- Official label/SmPC warnings and contraindications (currently a Blocking data gap)
- Confirmed mechanism of action data from DrugBank (currently a High-severity data gap)
- A clearer clinical definition distinguishing “neurotic disorder” from the already-approved MDD indication
- A purpose-designed clinical study (ideally RCT) targeting this specific diagnostic population, rather than reliance on indirect real-world cohort data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.